These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18474025)

  • 1. Ibandronate in benign bone disease.
    Winzenberg T; Jones G
    Rev Recent Clin Trials; 2008 May; 3(2):139-49. PubMed ID: 18474025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
    Sambrook P
    Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Frampton JE; Perry CM
    Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
    Ringe JD; Body JJ
    Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate in profile: drug characteristics and clinical efficacy.
    Reginster JY; Neuprez A; Bruyère O
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):941-51. PubMed ID: 18624681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density--ESTHER study.
    Vujasinović-Stupar N; Milić N; Petrović-Rackov L; Prodanović N; Mijailović-Ivković M; Grujić Z; Buković S; Novković S; Pasalić-Simić K; Petrović V; Vukasinović D; Perunicić G;
    Srp Arh Celok Lek; 2010; 138(1-2):56-61. PubMed ID: 20422911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
    Ettinger MP; Felsenberg D; Harris ST; Wasnich R; Skag A; Hiltbrunner V; Wilson K; Schimmer RC; Miller PD
    J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ibandronate on bone quality: preclinical studies.
    Bauss F; Dempster DW
    Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
    Chesnut CH
    Drugs; 2006; 66(10):1351-9. PubMed ID: 16903769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
    Harris ST; Blumentals WA; Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.